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A B S T R A C T
Background
The global spread of multidrug-resistant malaria parasites has led to an urgent need for new 
chemotherapeutic agents. Drug discovery is primarily directed to the asexual blood stages, and 
few drugs that are effective against the obligatory liver stages, from which the pathogenic 
blood infection is initiated, have become available since primaquine was deployed in the 1950s.
Methods and Findings
Using bioassay-guided fractionation based on the parasite's hepatic stage, we have isolated a 
novel morphinan alkaloid, tazopsine, from a plant traditionally used against malaria in 
Madagascar. This compound and readily obtained semisynthetic derivatives were tested for 
inhibitory activity against liver stage development in vitro (P. falciparum and P. yoelii) and in 
vivo (P. yoelii). Tazopsine fully inhibited the development of P. yoelii (50% inhibitory 
concentration [IC50] 3.1 iM , therapeutic index [TI] 14) and P. falciparum (IC50 4.2 iM , TI 7) 
hepatic parasites in cultured primary hepatocytes, with inhibition being most pronounced 
during the early developmental stages. One derivative, N-cyclopentyl-tazopsine (NCP- 
tazopsine), with similar inhibitory activity was selected for its lower toxicity (IC50 3.3 iM , TI 
46, and IC50 42.4 iM , TI 60, on P. yoelii and P. falciparum hepatic stages in vitro, respectively). 
Oral administration of NCP-tazopsine completely protected mice from a sporozoite challenge. 
Unlike the parent molecule, the derivative was uniquely active against Plasmodium hepatic 
stages.
Conclusions
A readily obtained semisynthetic derivative of a plant-derived compound, tazopsine, has 
been shown to be specifically active against the liver stage, but inactive against the blood 
forms of the malaria parasite. This unique specificity in an antimalarial drug severely restricts 
the pressure for the selection of drug resistance to a parasite stage limited both in numbers 
and duration, thus allowing researchers to envisage the incorporation of a true causal 
prophylactic in malaria control programs.
The Editors' Summary o f this article follows the references.
PLoS Medicine | www.plosmedicine.org 2392 December 2006 | Volume 3 | Issue 12 | e513
Alkaloids against Malaria Liver Stages
Introduction
Malaria re-em erged abruptly in the highlands of Madagas­
car in the mid-1980s and was associated with large-scale 
mortality and m orbidity in the nonim m une inhabitants [1]. 
Shortage of antim alarial drugs, mainly chloroquine, led the 
population to rely on traditional herbal remedies. In a 
subsequent large-scale ethnobotanical survey, 229 p lant 
species, of which 30% are endemic to Madagascar, were 
reported  to possess antim alarial activity [2], although the 
m anner in which they are adm inistered was not recorded. 
One of the endemic plants, Strychnopsis thouarsii (Menisper- 
maceae) [3,4], was selected for fu rther investigations, because 
it is the sole ingredient of a widely used remedy reputed  to 
provide protection specifically against m alaria [5].
The traditional decoction, p repared simply by boiling S. 
thouarsii stem bark in water, showed only weak activity in vitro 
against the FcB1 strain of P. falciparum erythrocytic stages 
(50% inhibitory concentration [IC50] 34.0 ± 9.4 ig/ml). Given 
th a t some m edicinal p repara tions are also used as a 
preventive (for example, during epidemics), we hypothesized 
that this particular remedy, and others that are similarly 
poorly active against the blood stage parasites, might actually 
be active against the initial pre-erythrocytic (PE) phase of the 
infection [6]. This phase represents the invasion of hepato- 
cytes by the sporozoites inoculated by the mosquito and the 
full developm ent of the hepatic parasites from  which the 
pathogenic erythrocytic phase originates. Full inhibition of 
the PE stages of the infection provides true causal prophy­
laxis whereby the blood stage infection and its associated 
clinical m anifestations would be totally prevented. For P. 
vivax and P. ovale, in which dorm ant hepatic forms, the 
hypnozoites, can give rise to relapses in humans, drugs active 
against hypnozoites would provide a radical cure of the 
infection. In drug discovery programs, routine screening for 
anti-PE stage activity is seldom carried out, partly because 
these stages are clinically silent, bu t mainly because access to 
PE parasites is costly and restricted to a few laboratories. We 
aimed to establish whether the traditional remedy prepared 
from  S. thouarsii contained agents active against Plasmodium 
hepatic stages, and if so, to isolate them  and explore their 
suitability as future lead compounds.
Methods
Drugs
Tazopsine, [a]D22 -46° (c 0.5, MeOH) and HRCIMS m/z 
350.1608 [M+H]+, was purified from  Strychnopsis thouarsii stem 
bark collected in the eastern rain forest of Madagascar at 
Andasibe N ational Park. N -cyclopentyl-tazopsine (NCP-ta- 
zopsine), [a]D22 -30° (c 0.03, MeOH) and HRCIMS m/z 
418.2239 [M+H]+, was obtained from  tazopsine by a classical 
m ethod of am ine reductive alkylation [7]. Briefly, 200 i l  (2.3 
mmol) of cyclopentanone and 150 mg (2.4 mmol) of sodium 
cyanoborohydride (Fluka, Buchs, Switzerland) were added 
successively to 700 mg (2 mmol) of tazopsine solubilized in 5 
ml of absolute m ethanol and stirred at room  tem perature 
under argon for 24 h. A fter removal of the solvent under 
reduced pressure, the residue was acidified with 1 N HCl, 
then basified with NH4OH, dried and purified by a silica gel 
column chrom atography eluted with dichlorom ethane-m eth- 
anol-20%  am m onia (90-10-1). A total of 675 mg (1.62 mmol)
of NCP-tazopsine were obtained (81% yield). Prim aquine was 
purchased from  Sigma (Saint-Quentin Fallavier, France).
In Vitro Assay for P. yoelii and P. falciparum  Liver Stage 
Inhibition
P. yoelii (265 BY strain) and P. falciparum (NF 54 strain) 
sporozoites were obtained by dissection of infected Anopheles 
stephensi salivary glands. Prim ary mouse hepatocytes were 
isolated as previously described [8] and seeded in eight-well 
Lab-Tek plastic cham ber slides (VWR, Fontenay-sous-Bois, 
France) previously coated  with rat-ta il collagen I (BD 
Biosciences, Le Pont de Claix, France) at a density of 10 
cells per well. Mouse hepatocytes were cultured at 37 °C in 
5% CO 2 in William’s E medium supplem ented with 10% fetal 
calf serum, 1% L-glutamine, 1% sodium pyruvate, 1% 
insulin-transferrin-selenium , 1% nonessential amino acids, 
and 1% penicillin-streptom ycin (all from  Invitrogen, Cergy- 
Pontoise, France), for 24 h before inoculation of P. yoelii 
sporozoites (105 per well). H um an liver fragments were 
collected following inform ed consent provided from  patients 
undergoing a partial hepatectomy. The collection and use of 
these tissues were undertaken in accordance with French 
Governm ent ethical regulations. Prim ary hum an hepatocytes 
were isolated from  the healthy parts of these liver biopsies as 
previously described [9]. Hum an hepatocytes were seeded in 
LabTek plastic cham ber slides coated with collagen, at a 
density of 1.8 X 105 cells per well and cultured at 37 °C in 5% 
CO 2 in the same medium as above, supplem ented with 10-7 M 
dexam ethasone (Sigma) and 2% DMSO after com plete cell 
adherence (12-24 h), for at least 48 h before inoculation of P. 
falciparum sporozoites (10 per well). For a standard assay, the 
p lant extract, the purified com pound, o r prim aquine was 
solubilized in DMSO, fu rther diluted in culture medium 
(equal DMSO concentrations of <0.3%  per well), and then 
added to hepatocyte cultures at the time of sporozoite 
inoculation. Three hours later, after sporozoite penetration  
into hepatocytes, cultures were washed and fu rther incubated 
in the presence of the drug. Culture medium  containing the 
appropriate  drug concentration was changed daily until 48 h 
for P. yoelii, o r until 5 d for P. falciparum. Parasites were 
quantified on the last day of incubation. For the in vitro 
tim ing experiments, tazopsine treatm ent of P. yoelii and P. 
falciparum cultures was undertaken for different periods 
during the cultivation: 0 h to 3 h, 3 h to 24 h, o r 24 h to 48 
h after P. yoelii sporozoite inoculation (quantification at 48 h), 
or 0 h to 2 d, or 3 d to 5 d after P. falciparum sporozoite 
inoculation (quantification at 5 d). Parasite quantification was 
done by immunofluorescence analysis following fixation of 
the cultures with cold m ethanol and parasite-specific staining 
by a mouse polyclonal serum raised against the P. falciparum 
hea t shock p ro te in  70 th a t also cross-reacts with the 
homologous protein  of P. yoelii, and revealed with FITC- 
conjugated goat anti-mouse immunoglobulin (Sigma) [8]. 
Cells were stained with Evans Blue (0.4%), and parasites and 
cells nuclei were stained with 1 ig/m l of diamidino-phenyl- 
indole (DAPI; Sigma). Parasite num bers were counted u nder a 
fluorescence m icroscope w ith a 25X ligh t m icroscope 
objective. IC50 values, the drug concentration at which a 
50% reduction in the num ber of parasites was observed, as 
com pared to the num ber in the DMSO control cultures, were 
derived from  two independent experim ents in which each 
concentration was tested in triplicate wells.
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In Vitro Assay for Cell Viability
Prim ary hepatocytes of mice or humans were prepared  as 
above and seeded in 96-well plates coated with collagen, at a 
density of 5 X 104 and 7 X 104 cells per well, respectively. 
Drugs were added to the culture medium, which was changed 
daily after 24 h or 48 h of incubation for mouse and hum an 
hepatocytes, respectively. A fter 48 h of drug exposure (mouse 
hepatocytes) o r 5 d (human hepatocytes), 50 i l  of neutral red 
(Sigma) at 0.02% in phosphate-buffered saline (PBS) were 
added per well and incubated for 24 additional hours [10]. 
Cultures were then washed with PBS and the neutral red 
extracted with 1% SDS from  viable cells and quantified by 
measuring the OD540 on a m icroplate autoreader photom eter 
(BioTek Instrum ents, Winooski, Verm ont, U nited States). The 
50% toxic concentration (TC50) values, the drug concen­
tration  at which a 50% reduction of red neutral incorpo­
ration was observed, as com pared to that incorporated  in the 
DMSO control cultures, were derived from  two independent 
experim ents in which each concentration was tested in 
quadruplicate.
Statistical Methods for IC50 and TC50 Estimations
IC50 and TC50 were calculated by nonlinear regression 
using four-param eter logistic curves on the SigmaPlot 10.0 
software (http://www.systat.com). Each IC50 or TC50 is ex­
pressed as a m ean between two independent experiments, 
followed by the standard erro r of the mean.
In Vitro Assay for P. falciparum  Blood Stages Inhibition
P. falciparum clone 3D7 (chloroquine sensitive) and clone 
FCR3 (chloroquine resistant) erythrocytic stages were cul­
tured  as described [11], and drug antiplasmodial activity was 
assessed by the standard m ethod [12] with m inor modifica­
tions. Briefly, the com pounds tazopsine and NCP-tazopsine 
solubilized in DMSO were fu rther diluted in RPMI before 
adding to parasite cultures (0.5% parasitemia, mainly young 
trophozoites, and 1.8% final hem atocrit), in a 2-fold dilution 
series. Plates were m aintained for 24 h at 37 °C in 5% CO 2. 
Then 0.5 iC i of [3H]-hypoxanthine was added to each well, 
and cultures were incubated for a fu rther 24 h. The growth 
inhibition was determ ined by com parison of the radioactivity 
incorporated  into the treated  cultures with that into the 
control cultures, by liquid scintillation counting.
In Vivo Assay for Activity on P. yoelii Infections
All animal were kept and used in accordance with institu­
tional guidelines and European regulations. Female 6-wk-old 
Swiss mice (Rene; Janvier, Le Genest-Saint-Isle, France) 
weighing 24-31 g were randomly allotted to five groups. 
The drug to be tested was adm inistered orally. Tazopsine was 
diluted in sterile water and NCP-tazopsine in sterile water 
with 10% of Tween 80 (Aldrich, Le Chesnay, France). The 
drugs were adm inistrated on days -1 , 0, +1, +2 (+40 h), and 
the mice challenged on day 0 by retro-orbital injection of P. 
yoelii (265 BY strain) sporozoites. Group 1 received 100 mg/kg/ 
day of tazopsine (n — 5), and group 2 received sterile water at 
the same times (controls, n — 5); groups 1 and 2 were 
challenged with 4,000 sporozoites. Group 3 received 100 mg/ 
kg/d of NCP-tazopsine (n — 5), group 4 received 200 mg/kg/d of 
NCP-tazopsine (n — 8), and group 5 received 10% Tween in 
sterile water (controls, n — 5); groups 3, 4, and 5 were 
challenged with 10,000 sporozoites. Parasites were enum er­
ated by blinded microscopic exam ination of Giemsa-stained 
tail-blood smears collected from  day 2 to day 23 post­
inoculation. A mouse was considered negative when no 
parasites could be observed in 20,000 red blood cells (50 fields 
under a 50X light microscope objective) on any day during 
the period of observation. The results presented were derived 
from  two independent duplicate experiments.
In o rder to test for inhibitory activity against P. yoelii blood 
stages, four groups of five naive mice were inoculated 
(intraperitoneally) with 106 P. yoelii-infected red blood cells 
on day 0. Three hours later, one group was treated  with 
tazopsine at 100 mg/kg, another with NCP-tazopsine at 200 
mg/kg, whereas the o ther two groups acted as controls 
(respectively, water and 10% Tween 80). The doses were 
repeated  daily until day +3. For the group treated  with NCP- 
tazopsine and its control group, the animals were anesthe- 
tised 2 h following the adm inistration of the last dose (day 
+3), and placed for 30 min over a cage with 100 female 
laboratory-bred A. stephensi. Oocysts were enum erated in 30 
mosquito midguts dissected 8 d later, and the num ber of 
sporozoites in the salivary glands dissected from  30 insects 
was ascertained a fu rther 7 d later. All the experim ents were 
perform ed in two independent duplicates, and enum eration 
of parasites in blood smears and mosquitoes was conducted 
in a blinded fashion.
Real-Time PCR Quantification of P. yoelii Parasites in 
Mouse Livers
Female 6-wk-old Swiss mice weighing 24-31 g were 
randomly allotted to three groups. The drug to be tested 
was adm inistrated orally on days -1 , 0, and +1. G roup 1 
received 100 mg/kg/d of NCP-tazopsine (n — 4), group 2 
received 200 mg/kg/d of NCP-tazopsine (n — 6), whereas the 
control group received Tween 80 at 10% in sterile water (n — 
5). Mice were challenged on day 0 by retro-orbital injection 
with 120,000 P. yoelii sporozoites and sacrificed 42-h post­
inoculation. A piece of liver (0.2 g) was harvested and total 
RNA extracted using the Micro to Midi kit (Invitrogen) 
according to the m anufacturer’s instructions. The detection 
and quantification of liver stage parasites were done as 
described [13] with m inor modifications. Five micrograms of 
total RNA were treated  with DNase from  the Turbo DNA-free 
kit (Ambion, H untingdon, U nited Kingdom) and reverse 
transcribed by Superscript II (Invitrogen) according to the 
m anufacturer’s instructions. A total of 6 i l  of the 300 i l  
obtained (an equivalent to 100 ng of the starting total RNA) 
were used per TaqM an PCR assay (MX4000 m ultiplex 
quantitative PCR system; Stratagene, La Jolla, California, 
U nited States). Gene-specific P. yoelii prim ers (forward 5'- 
T T A G A T T T T C T G G A G A C A A A C A A C T , r e v e r s e  5 '- 
TCCCTTAACTTTCGTTCTTGAT; Invitrogen) and a probe 
(5 '-6FA M -C G A A A G C A TTTG C C TA A A A TA C TTC C A T- 
BHQ1; MWG Biotech, Ebersberg, Germany) were designed 
from  the P. yoelii 265BY 18S rRNA sequence using the Prim er 
Express software (PE A pplied Biosystems, Courtaboeuf, 
France). Lack of nonspecific am plification with mouse 
genomic DNA was determ ined in prelim inary experim ent 
(unpublished data). Mouse ß-actin prim ers (forward 5'- 
ACGGCCAGGTCATCACTATTG, reverse 5'-CAAGAAG- 
GAAGGCTGGAAAAG; Invitrogen) and a probe (5'-HEX- 
CAACGAGCGGTTCCGATGCCC-BHQ2; MWG Biotech) 
were designed and used for normalization. Purified plasmids
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Figure 1. Structure of Tazopsine
Tazopine is shown on the left. The chemically modified substituents are indicated by asterisks (left): a single asterisk (*) indicates 4-OH protected by 4-O- 
alkylations; double asterisks (**) indicate 6,7-diol protected by an acetonide ketal; and triple asterisks (***) indicate secondary amine substituted by N- 
acetylation and N-alkylations. Structure of the semisynthetic alkaloid, NCP-tazopsine is shown on the right. 
doi:10.1371/journal.pmed.0030513.g001
(pCRII-TOPO) containing P. yoelii 18S rRNA and mouse ß- 
actin PCR fragments cloned with the TOPO TA cloning kit 
(Invitrogen) were used in a 10-fold dilution series to obtain a 
standard curve. All TaqMan test samples and plasmid stand­
ards were perform ed in triplicate. Absolute transcrip t copy 
num ber for each gene was calculated based on their external 
standard curves. For each sample, P. yoelii rRNA 18S absolute 
copies were normalized to 106 copies of mouse ß-actin.
Statistical Analysis
Statistical analysis was undertaken by one-way analysis of 
variance (ANOVA) tests coupled to Tukey HSD tests; in this 
la tter test, the exact p-value is given only if it exceeds 0.01.
Results
The activity of the S. thouarsii decoction was assessed in a 
standard bioassay of cultured mouse prim ary hepatocytes 
infected with P. yoelii sporozoites [14,15]. Parasite inhibition 
was observed in the exposed cultures (IC50 8.5 ± 0.7 ig/ml), 
with hepatic forms completely elim inated at concentrations 
of 20 ig/m l or greater. Toxicity, as assessed by red neutral 
incorporation  into the uninfected prim ary hepatocytes, was 
absent at the highest concentrations tested (100 ig/ml). In 
o rder to identify the compound(s) responsible for this 
activity, we conducted a bioassay-guided fractionation (Fig­
ure S1). The activity resided in the methanolic, but not the 
ethanolic extract (consistent with a highly polar compound), 
with an IC50 of 12.5 ± 3.5 ig/ml. Successive chrom atographic 
separations, m onitored by the in vitro P. yoelii liver stage 
inhibition assays, led to the isolation of a pure active 
com pound that we nam ed tazopsine which represented the 
m ajor constituent of the dry m aterial obtained from  the 
traditional decoction (10.3% w/w) (Figure S2). The structure 
of tazopsine was solved by two-dimensional 1H and 13C 
nuclear magnetic resonance (NMR) spectroscopy (Table S1). 
It consists of a m orphinan skeleton bearing two methoxyl 
groups at positions 3 and 8, and four hydroxyl groups at 
positions 4, 6, 7, and 10 (Figure 1), with a molecular weight of 
349. To the best of our knowledge, this structure had not 
been previously described.
Antimalarial Activity of Tazopsine
Purified tazopsine was found to be active against the liver 
stages of P. yoelii and those of P. falciparum. Total inhibition of 
cultured P. yoelii hepatic stages was obtained at 7.1 pM or 
g reater (IC50 3.1 ± 0.1 pM) in cultured prim ary hepatocytes 
(Figure 2A), yielding a therapeutic index (TI) of 14 (TC50 43.7 
± 1.6 iM). For P. falciparum -infected  prim ary hum an 
hepatocyte cultures [9], parasite developm ent was fully 
inhibited at higher concentrations of 28 iM  or greater (IC50 
4.2 ± 0.3 iM), and the corresponding TI using hum an 
prim ary hepatocytes (TC50 28.4 ± 4.3 iM ) was 7 (Figure 2A). 
Tazopsine was also active against the erythrocytic stages of P. 
falciparum in vitro (IC50 4.7 ± 0.9 pM using the 3D7 line, IC50 
5.7 ± 2.1 pM using the FCR3 line).
Exam ination of cultures subjected to suboptimal inhibitory 
concentrations revealed that tazopsine inhibited growth 
because the surviving hepatic parasites were significantly 
smaller than those observed in control cultures (Figure 2B 
and 2C). In order to determ ine the point at which the liver 
parasites were most susceptible to inhibition by tazopsine, we 
exposed P. yoelii hepatic cultures to suboptimal inhibitory 
concentrations at the different phases of the infection: the 
first 3 h postinfection (PI), by which time the sporozoites have 
invaded the hepatocytes; from  3 to 24 h PI, at the end of 
which, nuclear division has just been initiated in the growing 
trophozoites; and finally, from  24 to 48 h PI when the 
schizonts were m aturing  to large m ultinucleate forms. 
Sporozoite invasion and differentiation into early hepatic 
stages were not affected by tazopsine, nor did pretreatm ent 
of sporozoites with tazopsine alter hepatocyte invasion 
efficiency (Figure 3A). Inhibition was the most pronounced 
during the early developmental stages of the hepatic parasite 
(3 to 24 h), with only residual inhibitory activity on growing 
young schizonts (24 to 48 h) (Figure 3A). In parallel experi­
ments, P. falciparum hepatic stages were similarly found to be 
most susceptible to inhibition during the early stage of 
trophozoite developm ent (Figure 3B). For both parasite 
species, the inhibitory effect was found to be dose dependent 
(Figure 3). It should be pointed out that hepatic stages of P. 
yoelii and P. falciparum differ in the time required  for 
m atu ra tion  in to  form s contain ing  invasive m erozoites.
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Table 1. Comparative Inhibitory Activities o f Tazopsine, NCP-Tazopsine, and Primaquine on Hepatic Stages Cultured in Primary 
Hepatocytes
Drug P. yoelii P. falciparum
IC50 ( lM ) IC90 ( lM ) TC50 ( lM ) TI IC50 ( lM ) IC90 ( lM ) TC50 ( lM ) TI
Tazopsine 3.1 ±  0.1 6.3 ±  0.8 43.7 ±  1.6 14 4.2 ±  0.1 18.3 ±  2.8 28.4 ±  4.3 7
NCP-tazopsine 3.3 ±  0.05 5.2 ±  1.4 150.5 ±  9.5 46 42.4 95.4 ±  6.6 2,549.6 ±  307.6 60
Primaquine 0.64 ±  0.1 > 3 0 70.5 ±  4.3 1 1 0 0.80 ±  0.9 4.1 ±  0.5 65.2 ±  11.9 81
doi:10.1371/journal.pmed.0030513.t001
Development is com pleted at the earliest in 45 h for P. yoelii, 
and in 5.5 to 6 d fo r P. falciparum. For bo th  species, 
m aturation takes longer in cultured prim ary hepatocytes. 
Nonetheless, the P. yoelii model has been extensively used for 
biological, immunological, and chem otherapeutical investi­
gations; and to a large extent, similar findings were observed 
when the corresponding studies were carried out using P. 
falciparum [16-18].
Hepatic Stage Specificity and Protective Efficacy of NCP- 
Tazopsine
Prelim inary experim ents established that tazopsine was 
toxic to mice at oral doses exceeding 100 mg/kg given daily 
over 4 d (the standard num ber of doses in this m alaria 
model). U pon challenge with 4,000 P. yoelii sporozoites, 
protection from  infection was obtained in 70% of the mice 
treated  at 100 mg/kg daily for 4 d, whereas the rem aining 30% 
developed a blood stage parasitemia, albeit the ir p repaten t 
period (the time from  inoculation until parasites become 
microscopically detectable) was extended by about 4 d over 
that of the controls (Figure 4). In o rder to determ ine whether 
protection  from  infection might be in p art due to an 
additional effect of tazopsine on the blood stage parasite, 
groups of mice were treated  as above and challenged on day 0 
with P. yoelii-infected  blood. No significant inhibition of the 
erythrocytic m ultiplication cycle could be detected (unpub­
lished data). This confirmed that the protection was due to an 
inhibition of the hepatic stages.
The toxicity of tazopsine in mice and on cultured hum an 
cells was of concern. We, therefore, synthesized a series of 
derivatives from  tazopsine, and those still found active 
against cultured P. yoelii (IC50 <  50 lM), were tested for 
toxicity. Of the seven substituents of tazopsine, four were 
targeted because they were amenable to functionalization by 
classical alkylation: the three hydroxyl groups at positions 4,
6, and 7, and the secondary am ine (Figure 1). Whereas 
alkylation of the three hydroxyl groups led to a com plete loss 
of activity, inhibition of liver stages was retained by seven of 
the ten semisynthesized N-alkylated derivatives. Their IC50 
values, determ ined using the hepatic P. yoelii inhibition assay, 
ranged from  3.3 iM  to 24 iM . NCP-tazopsine had the lowest 
IC50 (3.3 ± 0.05 iM ) and the lowest toxicity to cultured 
prim ary mouse hepatocytes (TC50 1 50.5 ± 9.5 iM). These 
values are a significant im provem ent on tazopsine, yielding a 
TI of 46 for NCP-tazopsine (Figure 4A). Dose-dependent 
inhibition of P. falciparum hepatic stages was also obtained 
with NCP-tazopsine, with an IC50 of 42.4 iM  and a TC50 for 
prim ary hum an hepatocytes of 2,549.6 ± 307.6 iM , resulting
in a TI of 60 (Figure 4A), again a m ore adequate value than 
that of tazopsine. Furtherm ore, NCP-tazopsine did not have 
any detectable effect on the m ultiplication in v itro-cultured  
erythrocytic P. falciparum (both the 3D7 and the FCR3 lines) 
up to concentrations of 600 iM . By way of com parison, the 
activity of prim aquine, the only drug licensed for use against 
the parasite’s hepatic forms, has been determ ined in parallel 
in the same model systems (Table 1). The IC50 for prim aquine 
is close to 1 iM  for both  parasite species, and although it is 
significantly m ore active than NCP-tazopsine on P. falciparum, 
similar therapeutic indices were observed with the two 
molecules for this parasite species.
Oral adm inistration of NCP-tazopsine up to doses of 400 
mg/kg for 4 d was no t found to be toxic to mice. When mice 
treated  with daily 200 mg/kg doses over 4 d were challenged 
with 10,000 P. yoelii sporozoites, none of the mice developed a 
blood stage infection (Figure 4B). A t subdoses of 100 mg/kg for
4 d, 60% of the mice challenged were pro tected  from  
infection, and the p repaten t period of the nonprotected  
mice was extended by 2 d over controls, indicating a 
substantial reduction in the num ber of liver parasites [19]. 
A dm inistration of the drug NCP-tazopsine at this fully 
protective dose to animals inoculated with P. yoelii-infected  
blood had no effect on blood stage parasite m ultiplication 
(unpublished data). Analysis of female A. stephensi mosquitoes 
fed on treated  and un treated  mice, revealed that NCP- 
tazopsine had no effect on the transmissibility of the parasite 
(unpublished data). These observations confirmed that NCP- 
tazopsine is only active against the hepatic phase of the life 
cycle. This result was fu rther confirmed through quantifica­
tion by real-time PCR, perform ed on RNA purified from  the 
livers of another group of mice challenged with a massive 
sporozoite dose (120,000 parasites) and treated  with NCP- 
tazopsine. As com pared to controls, parasite loads at 42 h PI 
in the animals treated  with the fully protective dose were 
reduced by 99.98%, and those at the suboptim al dose by 
98.58% (Figure 4C).
Discussion
We have described a naturally occurring  m orphinan, 
tazopsine, that can be readily isolated in high yields (0.56% 
w/w) from  the stem bark of S. thouarsii. This com pound 
represents a novel class of antim alarial drugs and possesses 
outstanding inhibitory activity against the Plasmodium hepatic 
stages (Patents: Priority Europe No 04 291 055.4 April 22 
2004; International Patent Application 21 April 2005 No 
PCT/EP 2005/005239). Tazopsine represents one of the first
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Figure 2. Inhibitory Activity of Tazopsine on Plasmodium Hepatic Stages in vitro
(A) Representative curve of the dose-dependent inhibition of tazopsine (the number of parasite forms in test wells divided by the number of parasites in 
control wells) for graph a, P. yoelii (filled squares [■], average number in control wells =  274), and graph b, P. falciparum (filled circles [• ], average 
number in control wells =  83). Toxicity as assessed by the neutral red assay is presented for graph c, mouse (open squares [□]), or graph d, human (open 
circles [o]) primary hepatocytes. Results are means ±  standard deviation within triplicates of one experiment. R represents the factor of regression 
calculated by SigmaPlot.
(B) Dose-dependent influence on the size of surviving P. falciparum hepatic forms, (21 forms were counted for each point, and the bar represents the 
median value). Significance was calculated in one-way ANOVA analysis for the whole dataset (p <  0.0001), coupled to a Tukey HSD test: double asterisks 
(**) indicate p <  0.01.
(C) P. falciparum hepatic forms (arrow) from cultures treated with tazopsine (15 iM ) for 5 d, or untreated control cultures. DAPI staining is shown in the 
right images, and P. falciparum-specific staining (anti-PfHSP70 antibodies) in the left images. N, hepatocyte nucleus. The bar represents 5 im . 
doi:10.1371/journal.pmed.0030513.g002
plant-derived molecules to be chemically characterized with 
activity against the parasite’s hepatic stage.
Exposure to tazopsine prevented the in vitro development 
of P. falciparum and P. yoelii, although with relatively low 
therapeutic indices. The semisynthetic derivative NCP-tazop-
Figure 3. Susceptibility of Plasmodium Hepatic Stages to Tazopsine 
during Growth
It should be noted that the in vivo duration of the hepatic phase of P. 
yoelii is 44 to 48 h, whereas that of P. falciparum is just under 6 d.
(A) P. yoelii cultures were subjected to 3 iM  (IC50; open bars) or 5 iM  
(IC80; filled bars) of tazopsine for different periods of the development. 
Preincubation of 80,000 sporozoites (Spz) in the presence of 5 iM  or 100 
iM  of tazopsine for 1 h or 3 h, respectively, were carried out at room 
temperature prior to washing and being added to the mouse primary 
hepatocyte well.
(B) P. falciparum cultures were subjected to 4 iM  (IC50; open bars) or 10 
iM  (IC80; filled bars) of tazopsine for different periods of development. 
Inhibition was measured as the number of parasite forms in test wells 
divided by the number of parasites in control wells, for P. yoelii, the 
average number in control wells equaled 408, and for P. falciparum, 105. 
Results are means ±  standard deviation. 
doi:10.1371/journal.pmed.0030513.g003
sine, p repared through simple amino alkylation, showed 
substantially improved therapeutic indices in vitro and fully 
protected  mice against a large sporozoite challenge when 
adm inistered orally. The IC50 values and the therapeutic 
indices of NCP-tazopsine do not differ substantially from 
those of the licensed prim aquine (Table 1). It is noteworthy 
that the few chemical modifications of tazopsine attem pted to 
date have led to a com pound, NCP-tazopsine, with signifi­
cantly reduced toxicity and which have lost activity against P. 
falciparum blood stages in vitro. It is likely that fu rther 
derivatizations, to which tazopsine is readily amenable, would 
generate one or m ore com pounds with improved pharm aco­
logical characteristics. O ther m orphinans, such as the opioids 
m orphine, codeine, and thebaine, were not found to be 
inhibitory when tested against the P. yoelii liver stages (IC50 >  
100 pM). Indeed these m orphinans differed from  tazopsine 
and NCP-tazopsine mainly by the inverse absolute config­
uration  of asymmetric carbons on the piperidine ring. It 
would thus seem that the known targets of m orphine-related 
compounds are not implicated in the mechanism of action of 
tazopsine and NCP-tazopsine, which remains at present 
speculative. Classical biochemical and pharmacological in ­
vestigations of Plasmodium liver stages are severely ham pered 
by the nonavailability of purified infected hepatocytes.
The urgent need to counter the emergence and global 
spread of drug-resistant P. falciparum parasites has favored the 
search for novel blood schizontocides to the detrim ent of 
causal prophylactic agents. Furtherm ore, given the logistic 
obstacles to screening com pounds for activity against the 
hepatic stage, namely the simultaneous availability of prim ary 
hepatocytes and sporozoites, only a m inor fraction of the 
com pounds screened for anti-asexual-stage activity are 
assayed against the infected hepatocyte. Consequently, there 
is a lim ited num ber of drugs effective against the Plasmodium 
liver stage parasite. The deployment of prim aquine, the only 
drug specifically developed to inhibit the liver infection, has 
been curtailed by the associated toxicity, poor compliance, 
and increased risk of hemolysis when adm inistered to persons 
with glucose-6-phosphate dehydrogenase deficiency. This 
latter problem  will also affect the two related synthetic 8- 
am inoquinolines, bulaquine [20] and tafenoquine [21], 
presently undergoing clinical trials. Antifolates and atova­
quone, primarily used in com bination to treat the blood stage 
infection, were also shown to be active against the infected 
hepatocyte. However, the high prevalence of resistant para­
sites to the former, and the ease with which resistance arises 
to the latter, limit the prophylactic usefulness of these drugs. 
Quinine, chloroquine, mefloquine, and artem isinin-based 
compounds, have little or no efficacy against the hepatic 
parasite. Experimental com pounds belonging to o ther chem­
ical classes, e.g., antibiotics [22], antihistaminics [23], or
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Figure 4. Inhibitory Activity of NCP-Tazopsine on Plasmodium Hepatic Stages in vitro and Protective Activity of Tazopsine and NCP-Tazopsine for P. 
yoelii Infections in vivo
(A) Representative curve of the dose-dependent inhibition of NCP-tazopsine (the number of parasite forms in test wells divided by the number of 
parasites in control wells) for (graph a) P. yoelii (filled squares [■], average number in control wells =  152), and (graph b) P. falciparum (filled circles [•],
jV PLoS Medicine | www.plosmedicine.org 2399 December 2006 | Volume 3 | Issue 12 | e513
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average number in control wells =  384). Toxicity is presented for (graph c) mouse (open squares [□]) or (graph d) human (open circle [*>]) primary 
hepatocytes. Results are means ±  standard deviation within triplicates of one experiment.
(B) Proportion o f mice that failed to acquire a blood-stage infection following sporozoite challenge through treatment with tazopsine (filled diamonds 
[♦], 100 mg/kg), NCP-tazopsine (filled circles [• ], 100 mg/kg, and open circles [*>], 200 mg/kg), distilled water or 10% Tween in distilled water (asterisks 
[*] indicate control groups).
(C) Dose-dependent reduction of hepatic parasite load by NCP-tazopsine following sporozoite challenge. Bar represents the average value. Significance 
was calculated in one-way ANOVA analysis for the whole dataset (p =  0.0012), coupled to a Tukey HSD test: double asterisks (**) indicate p <  0.01. 
doi:10.1371/journal.pmed.0030513.g004
anticancer drugs [24] have been reported  to have activity 
against the PE stages of Plasmodium. Most of these were tested 
only on rodent malaria parasites and in which they were also 
active against the b lood  stages. Two quinoline esters 
prevented relapse of P. cynomolgi in monkeys [25], as did two 
imidazolidinedione com pounds prepared  from  the antifolate 
chlorproguanil [26]. Although the first had additional activity 
against blood stage parasites, the two im idazolidinedione 
molecules proved not to inhibit the erythrocytic stages of P. 
berghei in mice nor those of P. falciparum in vitro [27]. The 
hepatic stage specificity of the imidazolidinediones and NCP- 
tazopsine places these lead molecules from  two distinct 
chemical classes into a novel category of antim alarial 
com pounds with true causal prophylactic activity.
Although tazopsine constitutes a suitable lead candidate 
for fu rther optim ization, there are a num ber of issues that 
would need to be addressed before it reaches the status of a 
drug candidate. Toxicity is a very im portan t param eter since 
a drug aimed for prophylactic use will by definition be 
adm inistered over long periods of time. Two aspects of the 
results are of some encouragem ent in this context. Deriva­
tives, such as NCP-tazopsine, that retain  inhibitory activity 
yet have significantly reduced toxicity as com pared to the 
paren t com pound tazopsine, were readily obtained. The 
recent developm ent of high-throughput screening of drug 
activity on Plasmodium hepatic stages [28] should enhance lead 
optim ization, and provide candidates for pharm aceutical 
optim ization (adsorption, distribution, metabolism and ex­
cretion [ADME]). Full protection from  an in vivo challenge 
was afforded by oral adm inistra tion  of NCP-tazopsine, 
although it remains to be dem onstrated that a similar route 
of intake will be equally effective in primates. As com pared to 
blood schizontocides in which inhibitory activity is observed 
in the low nM range, the iM  concentrations of tazopsine and 
NCP-tazopsine required for the inhibitory activity of hepatic 
stages in vitro were relatively modest. The equivalent values 
for prim aquine (0.64 iM  and 0.8 iM  for the P. yoelii and P. 
falciparum liver stages in vitro), were also close to 1 iM  (Table 
1). These high concentrations, relative to blood schizonto- 
cides, might reflect the fact that the target of the drug is 
found within the cells of the liver, a metabolically complex 
and active organ in part devoted to detoxification.
Historically, a prim ary aim of antim alarial drug research 
has been to develop a true causal prophylactic. These efforts 
were much diminished by the introduction of the remarkably 
successful chloroquine after the second W orld War, although 
the high rate of P. vivax relapses in military personnel 
returning to the U nited States from  Korea in the early 1950s 
led to prim aquine [29], a drug still primarily used to effect the 
radical cure of P. vivax and P. ovale by preventing relapses due 
to hypnozoites. The fact that all antimalarials used to date 
with true prophylactic activity also inhibit the erythrocytic 
stages precludes any consideration of mass adm inistration. 
This is because exposure of blood stage parasites, in which
cyclical m ultiplication leads to high parasite loads and the 
persistence of millions of parasites in the hum an host for 
many weeks or months, to subcurative drug concentrations 
exerts substantial pressure that would lead to the selection 
and dissemination of drug-resistant parasites. This exposure 
to selective drug pressure constitutes a m ajor im pedim ent to 
efforts aimed at developing novel causal prophylactic com ­
pounds. A drug active solely against the liver stages would 
exert only marginal selective pressure, since a single infective 
bite leads to an average of a few dozen hepatic stage parasites 
that usually persist for less than 2 wk, during which they 
undergo a single multiplicative expansion. The deployment 
of such a drug would be especially valuable in containing the 
spread of the disease in areas of emerging or epidemic 
malaria, and in residents subjected to seasonal transmission. 
It would be the ideal choice for transient visitors to endemic 
areas, such as displaced populations, tourists, and the 
military. In populations residing in areas of higher endemic- 
ity, the drug would help reduce the effective dose of 
infectious sporozoites, even if deploym ent is suboptimal. 
The consequences of modest reductions in hepatic stage 
parasite num bers might have disproportionate beneficial 
consequences on malaria morbidity, as suggested by the 
results of one of the Phase IIb trials of the anti-PE vaccine 
RTS,S [30,31]. Moreover, adm inistration of this type of drug 
would not impede natural boosting of imm une responses 
against PE or erythrocytic stage parasites.
In conclusion, the discovery of molecules with exclusive 
action against the hepatic phase of the life cycle lays the 
foundations to re-evaluate causal prophylaxis as a tool that 
can be incorporated  in control strategies and enhance global 
efforts to reduce the m ajor burden exacted by malaria.
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Editors' Summary
Background. The parasite that causes malaria has quickly developed 
resistance to many of the drugs that are commonly used to treat this 
disease. As a result, new drugs and drug combinations are needed. In 
some parts o f the world where antimalarial drugs are failing due to 
resistance, or are not available to everyone, people often turn to 
traditional herbal remedies instead. These traditional plant remedies can 
be a useful starting point for development o f new drugs, but the process 
o f developing effective new drugs from plant remedies is long and 
complicated. An important initial step is to isolate and identify the active 
compounds from plants and then see how well these compounds 
perform against malaria parasites in laboratory tests. If the tests are 
successful, such compounds could then progress to experiments in 
animals and possibly eventually human trials. One plant used widely in 
Madagascar for treatment of malaria is Strychnopsis thouarsii; the 
traditional remedy consists of the plant stem bark boiled in water.
Why Was This Study Done? The group o f researchers doing this study 
wanted to discover candidates for new malaria drugs. They therefore 
wanted to find out which molecular compounds in the stem bark of S. 
thouarsii contained antimalarial activity, and what particular stage of the 
malaria parasite's life cycle these compounds had an effect on. The 
researchers suspected that the agents in this plant bark had some 
activity against the ‘‘ liver stage’’ o f malaria infection in humans. This is 
the first stage of infection, after a person has been bitten by a malaria- 
infected mosquito, and before blood cells are invaded by malaria 
parasites (which then causes the disease symptoms). Very few drugs 
currently in existence have an effect on the ‘‘ liver stage’’ o f infection, but 
activity at this stage would be tremendously useful because it could 
mean a drug is better for prevention of malaria than others in existence.
W hat Did the Researchers Do and Find? First, the researchers wanted 
to take the traditional herbal remedy—of S. thouarsii bark boiled in 
water— and find out precisely which molecule in that remedy was 
responsible for the antimalarial activity. They therefore used a method 
called chromatography to progressively separate the herbal extract into 
its distinct components. At each stage of separation, the extract was 
checked for activity against malaria using a laboratory test. Inactive 
extracts were disregarded, and the active component then taken on to a 
further separation round. After many rounds o f separation and testing, 
the researchers got down to a single, apparently new, molecule that was 
active against malaria in the laboratory test, and this molecule was
named tazopsine (in the Malagasy language the word Tazo refers to 
malaria). In order to find out how effective the molecule was at killing 
malaria parasites, the researchers took human or mouse liver cells 
cultured in the laboratory, infected them with malaria parasites (either 
the malaria parasite that normally infects humans, or a related species 
that infects mice), and then added tazopsine at different concentrations. 
The compound completely killed the malaria parasites even at very low 
concentrations, and had activity against malaria infecting either liver cells 
or red blood cells. Tazopsine was then given to mice injected with a 
species of the malaria parasite. The compound protected most mice 
against malaria infection when it was used at a dosage level lower than 
the toxic dose. The researchers then tried making a series of different 
variants of tazopsine in the hope that some variants would be less toxic, 
but equally active as, the original compound. They found one variant, 
named NCP-tazopsine, that was much less toxic but just as active as 
tazopsine, but only against the malaria infecting liver cells.
W hat Do These Findings Mean? In these experiments a new molecule, 
tazopsine, was discovered from a Malagasy plant, and it was found to be 
active against liver-stage malaria parasites, in laboratory experiments and 
in mice. This molecule or variants of it could in future become candidate 
antimalarial drugs in humans. However, much work would need to be 
done before testing could get to that stage. Different variants of 
molecules related to tazopsine would need to be tested to find one that 
has low toxicity, and these variants would need to be fully evaluated in 
animals to see how they are handled in the body before any trials could 
begin in humans.
Additiona l In form ation. Please access these Web sites via the online 
version o f this summary at http://dx.doi.org/10.1371/journal.pmed. 
0030513
•  The World Health Organization publishes a minisite containing links to 
information about all aspects of malaria worldwide, including 
treatment, prevention, and current programmes for malaria control
•  Medicines for Malaria Venture is a collaboration between public and 
private organizations (including the pharmaceutical industry) that 
aims to fund and manage the development of new drugs for 
treatment and prevention of malaria
•  Wikipedia entries for drug discovery and drug development (note: 
Wikipedia is an internet encyclopedia that anyone can edit)
PLoS Medicine | www.plosmedicine.org 2402 December 2006 | Volume 3 | Issue 12 | e513
